Chang-You Zhan

FAPi-Mediated siRNA Lipid Nanoparticles for the Treatment of Liver Fibrosis.

Liver fibrosis lacks effective therapies largely due to the inability of conventional lipid nanoparticles (LNPs) to target activated hepatic stellate cells (HSCs), the primary drivers of fibrotic progression. Here, we developed a fibroblast activation protein inhibitor (FAPi)-modified LNP encapsulating heat shock prote...